Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. No abstract available.

PMID:
30770493
2.

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1434.

3.

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.

Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5.

5.

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.

PMID:
14751502
6.

MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.

Gayle SS, Castellino RC, Buss MC, Nahta R.

Curr Med Chem. 2013;20(19):2486-99.

7.

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.

Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.

Breast Cancer Res. 2014 Jan 23;16(1):R9. doi: 10.1186/bcr3601.

8.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT Investigators.

Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494.

PMID:
28945833
9.

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.

Chung SS, Giehl N, Wu Y, Vadgama JV.

Int J Oncol. 2014 Feb;44(2):403-11. doi: 10.3892/ijo.2013.2195. Epub 2013 Nov 29.

10.
11.

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.

Cancer Res. 2013 Oct 1;73(19):6013-23. doi: 10.1158/0008-5472.CAN-13-1191. Epub 2013 Aug 5.

12.

Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells.

Nejatollahi F, Jaberipour M, Asgharpour M.

Tumour Biol. 2014 Aug;35(8):7887-95. doi: 10.1007/s13277-014-1854-8. Epub 2014 May 15.

PMID:
24828011
13.

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.

Alvarez RH, Hortobagyi GN.

Breast Cancer. 2013 Apr;20(2):103-10. doi: 10.1007/s12282-013-0446-6. Epub 2013 Feb 3. Review.

14.

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.

Advani P, Cornell L, Chumsri S, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2015 Sep 22;7:321-35. doi: 10.2147/BCTT.S90627. eCollection 2015. Review.

15.

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.

Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT.

Breast Cancer Res Treat. 2014 Jul;146(2):259-72. doi: 10.1007/s10549-014-3014-7. Epub 2014 Jun 12.

16.

Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

Young CD, Arteaga CL, Cook RS.

Breast Cancer Res. 2015 Dec 4;17:148. doi: 10.1186/s13058-015-0656-2.

17.

Her2 cross talk and therapeutic resistance in breast cancer.

Bender LM, Nahta R.

Front Biosci. 2008 May 1;13:3906-12. Review.

18.

The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.

Wang SE.

J Signal Transduct. 2011;2011:804236. doi: 10.1155/2011/804236. Epub 2011 Feb 24.

19.

Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells.

Do MT, Hwang YP, Kim HG, Na M, Jeong HG.

J Cell Physiol. 2013 May;228(5):1087-97. doi: 10.1002/jcp.24258.

PMID:
23065756
20.

New developments in the treatment of HER2-positive breast cancer.

Nahta R.

Breast Cancer (Dove Med Press). 2012 May 1;4:53-64.

Supplemental Content

Support Center